Trial Profile
A Phase II Study of Weekly Maintenance Bortezomib and Rituximab in Mantle Cell Lymphoma Post Autologous Hematopoietic Cell Transplantation.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jul 2023
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Rituximab (Primary)
- Indications Mantle-cell lymphoma
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- 15 Feb 2021 Status changed from active, no longer recruiting to completed.
- 13 Sep 2019 Planned End Date changed from 1 Jul 2019 to 7 Sep 2021.
- 17 Aug 2018 Planned End Date changed from 1 Jul 2018 to 1 Jul 2019.